Geneos Therapeutics

11:30 AM - 11:45 AM (PDT), Tuesday, June 14, 2022
Geneos Therapeutics is a VC backed, clinical stage immuno-oncology biotech company that is enabling its GT-EPICTM neoantigen targeting platform to develop personalized immunotherapies for cancer patients. The GT-EPICTM platform allows Geneos to develop exquisitely personalized DNA-based therapies tailored to each patient’s unique tumor mutations. Geneos is expanding its lead program, GT-30, is in advanced hepatocellular carcinoma (HCC), where it is evaluating its personalized neoantigen-targeting vaccine, GNOS-PV02,
Geneos is conducting an international, multi-center, GT-30 Phase Ib/IIa clinical program evaluating its personalized neoantigen-targeting vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. GNOS-PV02, which is based on Geneos’ proprietary GT-EPIC™ platform, is a tumor-specific DNA plasmid product designed and manufactured for each patient based on their unique tumor mutations’ (neoantigens)
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Pennsylvania
Company HQ Country:
United States
Year Founded:
2019
Main Therapeutic Focus:
Lead Product in Development:
GT-PV02
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Platform Product
Speaker
photo
CEO
Geneos Therapeutics, Inc.